Greg Russotti
Chief Technology & Manufacturing Officer, Century Therapeutics
Greg Russotti is listed as Chief Technology & Manufacturing Officer, Century Therapeutics. Greg is scheduled to speak at Advanced Therapies Week 2027 on 19 January 2027.
Compiled from published conference agendas; not yet confirmed by Greg. Is this you? Claim this profile.
About
Gregory Russotti is the Chief Technology and Manufacturing Officer at Century Therapeutics, a company developing iPSC-derived, allogeneic cell therapy products for Type I diabetes, hematology/oncology and autoimmune indications. Before joining Century in January 2020, Greg was Vice President of Cell Therapy Development and Operations at Celgene. During his 13 year tenure at Celgene, he guided CMC efforts for six different cell therapy products to IND and clinical stage development. Greg was also a leader in establishing in-house clinical manufacturing at Celgene and in building Celgene’s first commercial CAR T manufacturing facility. Prior to Celgene, Greg held various leadership roles at Merck Research Laboratories, developing vaccines and monoclonal antibodies for clinical and commercial manufacturing. Greg received his B.S. and M.S. degrees in Chemical Engineering from Rensselaer Polytechnic Institute and his Ph.D. in Chemical and Biochemical Engineering from Rutgers University.
Upcoming
Advanced Therapies Week 2027 19 January 2027 – 21 January 2027
- Session 1: Autologous and allogeneic cell therapies – what’s the latest progress in reducing process timeframes and cost of goods while enhancing scalability, quality, and consistency? Speaker · 19 January 2027
- Spotlight: Can the production of iPSC-derived beta islets for Type I diabetes be scaled up to be commercially viable? Speaker · 19 January 2027
- Session 5: Stepping back and reviewing the advanced therapy sector’s approach to automation Speaker · 20 January 2027
Spoke alongside
People who have shared a session with Greg at events on B2DB.
- Sarah Yuan Chief Technology Officer · Cabaletta Bio 2 shared sessions
- Dena Flamm Business Development Manager · OPTIMA packaging group GmbH 1 shared session
- Isabel Tian Senior Director, Scientific Affairs · Cellares 1 shared session
- Jeffrey Cram Vice President of Process Development · Elevatebio 1 shared session
- Jeffrey Graybill Vice President, CMC Commercial Strategy · Immatics 1 shared session
- Mamta Kalra Vice President Process and Analytical Development · Immatics 1 shared session
- Vilma Methner Senior Market Development Manager - ATMP · OPTIMA packaging group GmbH 1 shared session
- Xavier de Mollerat du Jeu Global Head of Automation · Legend Biotech 1 shared session